Evaluation of hepatitis B vaccine and its immuno therapeutic effect on HBs-Ag carriers

Abstract EN

This study included 117 cases classified into two groups.

Group I (included 65 HBs-Ag negative persons), Group II (included 52 HBsAg positive persons) and 26 HBsAg positive persons as a control group studied without vaccination Seroconversion rate at group I was significantly higher following the second and third dose of.

the vaccine in comparison withprevaccinationlevel(86.2%, 100%, 47.7%, respectively; P<0.0001).

Also, seroconversion following the third dose was significantly higher in group I than in group II (100%, 46.2%, respectively; P<0.0001).

The good responders (HBS-Ab level > 100 mlU/ml) was significantly higher P<0.001) in group I (86.2%) than in group II (32.7%).

Also, 53.8% of group II were found to have poor response to the vaccine while none were poor responders in group I (P<0.0001).

Following the 0, 1, 6 months schedule the responders were 94.9% with antibody level 9445 (6338 mlU/ml) which was highly significant (P<0.001) than responders to 0, 1, 2 months schedule (38.5%) with antibody response of 1210.5 (3423.7 ml U/ml).

In group II: 16 cases (30.8%) have converted to HBsAg -ve compared with 6 cases (23.1%) in controls with no statistical difference (P> 0.05).

The antibody response in cases with positive seroconversion in HbsAg is significantly higher (93.8%) than those with negative seroconversion in HbsAg (25%; p<0.001) and controls (33.3%; P<0.002).

HBV vaccine appears to be safe with no serious adverse effect regardless the serological state of vaccine recipient.

HB vaccine had no impact on HBsAg clearance which would have occurred as the natural course of acute HBV infection